Most Recent
Otsuka Pharmaceutical has hit back at suit filed by Indian generics company Sun Pharma seeking to invalidate its patent for blockbuster antipsychotic Abilify, filing a cross-claim seeking to restrain Sun Pharma from infringing the patent with a generic version of the drug.
In a continuing fight over damages stemming from misleading burger ads, McDonald's has opposed production of sales information to Hungry Jack's directors and its top executive, saying the information was confidential and the companies "fierce competitors".
Melbourne personal injury firm Law Partners Compensation Lawyers has successfully opposed a small Queensland firm’s registration of the name ‘Australian Law Partners’, with IP Australia saying ALP’s claim to distinctiveness was “not compelling.”
IP services giant IPH Limited, which owns IP boutiques Spruson & Ferguson and Griffith Hack, has made an offer worth $265 million to acquire its rival QANTM Limited, after failing to woo its main competitor with a takeover bid in 2018.
Hungry Jack’s is seeking five years of Big Mac sales data as it readies for a fight over damages stemming from its claim that its Big Jack burger has 25 per cent more beef than the McDonald's burger.
US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.
Indian generics company Sun Pharma has taken Otsuka Pharmaceutical to court, alleging an extension for the patent for an injectable form of the Japanese drug maker's blockbuster antipsychotic Abilify was wrongly granted and should be invalidated.
A Sanofi unit has lost its bid for more time to file a divisional application in relation to a hemophilia treatment, with an IP Australia delegate finding that a US lawyer's mistaken belief about Australian patent law did not explain the company’s failure to make the application in time.
A judge has rejected McDonald's claim that Hungry Jack's Big Jack burger infringed its Big Mac trade mark, but found that Hungry Jack's misled consumers by boasting that its burger had 25 per cent more beef.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.